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Abstract
Background: Foot complications are common in diabetic patients and are considered one of the
most expensive diabetes (DM) complications to treat. The aim of this study was to determine the
prevalence and risk factors for foot complications among diabetic patients in Al-Ain district, United
Arab Emirates (UAE).
Methods: The study was part of a general cross-sectional survey carried out to assess the
prevalence of DM complications in Al-Ain district, UAE. A sample of 513 diabetic patients with a
mean age of 53 years (SD: ± 13) were randomly selected during 2003/2004. All completed an
interviewer-administered questionnaire and underwent medical assessment including foot
examination and assessment of presence of peripheral neuropathy (PN) and peripheral vascular
disease (PVD).
Results:  Forty nine percent of the study populations were diagnosed to have DM without
presenting with symptoms of diabetes and 35% had hypertension. The majority (86%) had type 2
DM. Of the total sample, 39% (95% CI: 35.1-43.7%) had PN and 12% (95% CI: 8.8–14.4%) had PVD.
There were no cases of amputation and only one case had previous history of lower extremity
ulceration. Significant risk factors for PN and PVD were: male gender, poor level of education, UAE
nationality, increased duration of diabetes, type 2 DM, presence of hypertension and
microalbuminuria (MA).
Conclusion: Despite the low prevalence of foot ulceration and amputation among the study
population, nevertheless, a substantial proportion had potential risk factors for foot complications.
Background
Peripheral neuropathy (PN) and peripheral vascular dis-
ease (PVD) are well known common long-term complica-
tions of diabetes, and although a proportion of people
with PN and PVD have severe and debilitating pain, many
are asymptomatic [1]. However, despite the lack of symp-
toms, people with PN and PVD are known to be at high
risk of foot complications including foot ulceration, infec-
tion and amputation [2-4]. PN and PVD are the main
causes of non-traumatic lower limb amputation [5-7].
Complications affecting the lower limbs are among the
most common manifestations of diabetes; it was reported
that 15% of diabetic patients will eventually suffer from
foot ulceration during their lifetime [8]. These complica-
tions are a frequent cause of hospitalization and disabil-
ity; with 1 in 5 hospitalizations among diabetics directly
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related to foot ulcers [9]. Moreover, according to some
conservative estimates, the treatment costs of these com-
plications account for approximately 25% of total hospi-
tal costs of diabetes care, the true costs of which might be
an order of magnitude higher [10].
It is generally upheld that effective prevention of diabetic
foot requires in-depth knowledge of the pathogenesis and
clinical correlates of the complication; neither of which is
well understood so far [11]. Targeting patients at
increased risk for developing foot ulcer is believed to con-
stitute a cost effective strategy to control progression to
end stage complications. Evidence in the literature sug-
gests that the early detection and treatment of diabetic
foot complications could reduce the prevalence of ulcera-
tion by 44% to 85% [12,13].
The International Diabetes Federation (IDF) in 2003
ranked the UAE's prevalence rates of type 2 DM and
impaired glucose tolerance (IGT) as the second highest in
the world (20% for DM and 26% for IGT) [14]; a serious
status which indicates the extent and gravity of the prob-
lem in the UAE population. Indeed, the disease and its
complications such as PVD and PN are likely to constitute
a sizable burden to the UAE society, the magnitude of
which is not yet known. To our best knowledge, this is the
first epidemiological study assessing the prevalence and
risk factors of foot complications among diabetic patients
in the UAE population. As such, it is hoped that the study
would lay the grounds for future efforts aiming to control
the problem.
Methods
Overall Design
The study was part of a general cross-sectional survey of
DM patients carried out to assess and establish the preva-
lence of DM complications including foot complications
among diabetic patients in the Al-Ain District, UAE. The
district is located in the interior lands of Abu Dhabi Emir-
ate and constitutes the second largest district there; with
an approximate population of 500,000 according to
recent estimates in the UAE.
Subjects and Setting
The sampling frame of this study included all UAE and
non-UAE diabetic patients of all ages and both genders,
attending any PHCC for any reason or any diabetic clinic
at hospitals for follow up in Al-Ain district. Sample size
estimations were based on the general requirement that
prevalence estimates should have an (absolute) standard
error of no more than 0.02 (2%). Accordingly, a sample
size of 625 was calculated. In order to obtain a represent-
ative sample, multistage random sampling was used. To
achieve that all primary health care centers (PHCC) and
diabetic clinics in the district were listed and enumerated
and from these 8 PHCC were selected (out of 22 rural and
urban PHCC), in addition to two diabetic clinics at the
two main public hospitals of Al-Ain. In the absence of a
diabetes registry or a computerized database for patients
in the district, systematic random sampling within these
units (centers/clinics) was used to select patients to be
approached for participation in the study. Thus, every
third DM patient visiting any of the participating centers
and clinics was approached. In total 600 patients were
approached by general practitioners and diabetologists,
out of whom 513 (86%) agreed to enroll. The study was
approved by the Ethics Committee of the Faculty of Med-
icine and Health Sciences of the UAE University.
Data Collection
After receiving informed consent, diabetic patients were
interviewed by their treating doctors about DM type, dura-
tion, treatment profile, level of control, presence or
absence of chronic DM complications including previous
ulcer/amputation of the lower limbs and presence of vas-
cular symptoms of cramps and/or claudications, neuro-
pathic symptoms of tingling, numbness, and burning
sensation with a 'stocking and glove' distribution. Addi-
tionally, the research nurse took measurement of patients'
blood pressure early in the morning and prior to drawing
blood samples while in the sitting position, using a stand-
ard mercury sphygmomanometer. The WHO definition of
hypertension was used in this study: systolic blood pres-
sure 160 mmHg or more and/or a diastolic blood pressure
95 mmHg or more, or on going treatment with antihyper-
tensive drugs. Height was measured without shoes, and
weight recorded while wearing indoor clothing. Body
mass index (BMI) (weight in Kg, divided by the square of
the height in m2) was calculated. The WHO (1977, 1979)
classification for BMI was used to estimate the degree of
obesity [15]. A standard 12- lead electrocardiogram (ECG)
was recorded for all patients. Fasting blood samples were
taken to assess lipid profile, blood sugar and glycated
hemoglobin (HbA1C) levels. Total lipid profile (total cho-
lesterol (TC), high density lipoprotein (HDL), TC/HDL
Ratio, low density lipoprotein (LDL) and triglycerides)
was measured by a capillary tube whole blood method
using the Cholesterol LDX lipid analyzer. Dyslipidaemia
was taken to be present when the total cholesterol was
>5.60 mmol/L and/or triglycerides >2.10 mmol/L, and/or
LDL >3.4 mmol/L, and or HDL <0.91 mmol/L. Glycated
haemoglobin (HbA1C) was measured using the Bayer
DCA 2000+ analyzer and a value of less than 7% was
taken to indicate good glycemic control. Urinary albumin
concentration was measured by using semi-quantitative
dry immuno chemical screening strips (Micral 11® test
strips (Roche diagnostic GmbH Mannheim Germany).
Micral Tests were performed on first morning urine collec-
tions and a value of more than 20 µg/min was judged as
pathological.BMC Family Practice 2007, 8:59 http://www.biomedcentral.com/1471-2296/8/59
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Both feet were examined for signs of vasculopathy and
neuropathy including skin status (color, thickness, dry-
ness, cracking, trophic changes, decreased hair growth),
the nail status (color, thickness, trophic changes), and the
presence of deformities (such as claws and hammer toes),
oedema, infection, ulceration, callus and blistering. Gan-
grene and amputation were also noted.
PN was assessed by vibratory, monofilament, muscle
strength and tendon reflex testing. Pressure, pain, vibra-
tion and joint position sensitivities were evaluated bilater-
ally. For pressure perception, the 10 g Semmes-Weinstein
monofilaments was used on 4 sites of the foot. These sites
were without callus, notably the pulps of the hallux and
metatarsal heads of first, third and fifth toes. The site was
considered sensate if the patient responded, "yes" upon
contact with the monofilament and insensate if there was
no response.
For vibration perception, a 128 Hz tuning fork was
applied at 3 sites on the foot, the pulp of the hallux, the
lateral and the medial malleoli. The patient was asked to
describe what he felt. If he/she described a feeling of vibra-
tions, the site concerned was considered normal. If he/she
described anything other than vibrations, the site con-
cerned was considered abnormal. In addition, pin-prick
perception (using standard neurotips) on the dorsal sur-
face of the great toe and the index finger were evaluated.
Neuropathy was further assessed by examining the tendon
reflexes bilaterally and testing for muscle strength by
examining for extension of the knee and dorsiflexion of
the foot.
Diabetic Neuropathy Symptoms (DNS) [16] along with
the Diabetic Neuropathy Examination (DNE) scores [17]
were used together to define and assess neuropathy. Neu-
ropathy was considered to be present if DNS score was >0
and/or the DNE score was >3. Lower limb ischemia was
ascertained by the examining physician through palpa-
tion of the dorsalis pedis and the tibialis posterior pulses
when one or more foot pulses were judged absent with or
without symptoms of lower-limb claudication and/or
amputation or gangrene were present.
Statistical Analysis
The data was coded and processed on IBM compatible
computers, using the Statistical Package for Social Sci-
ences (SPSS) software (version 14). Descriptive analysis,
using standard statistical methods was performed. Chi-
square tests or Fisher's exact test, independent t-tests and
Pearson correlation coefficient were used to ascertain the
association between the outcome variables of foot com-
plications and their determinants; specifically relevant
clinical variables.
A multiple logistic regression model with backward selec-
tion (criterion: p-value to remove ≥ 0.10) was used to esti-
mate the simultaneous effect of several determinants of
neuropathy (PN) and peripheral vascular disease (PVD)
among the sample population. This method first enters all
independent variables selected by the researcher in the
logistic equation and then sequentially removes them,
starting with the least significant one, until all p-values are
below the chosen value 0.10 (p-value to remove).
For PN and PVD, the variables included as predictors were
sex, level of education (primary, intermediate, secondary
and university), age groups (categorical intervals in years),
type of DM, duration of disease (categorical intervals in
years), nationality groups (UAE, Gulf citizens, Asians,
Arabs of other nationalities and others). That is in addi-
tion to a number of determinants of dichotomous (yes/
no) outcome of PN including presence of retinopathy, MA
and glycemic control and of PVD including presence of
hypertension, MA and glycemic control. Missing values
(very few) for variables were imputed using mean imputa-
tion, i.e. they were substituted by the variable mean.
Analysis of variance (ANOVA), was used to estimate over-
all model performance, while estimated model standard
errors and t-tests were used to test for the significance of
individual (linear) regression parameters.
Results
Socio-Demographic Characteristics of the Study 
Population
The descriptive analysis of the sample showed that 52%
were males, 27% were aged 60 years or above, 75% were
UAE nationals and most of patients (63%) were illiterate.
Of the total sample 12.8% (95% CI: 11.0–14.6) were cur-
rent smokers while 8.2% (95%CI: 6.7–9.7) were ex-smok-
ers (Table 1).
Clinical Characteristics
Of the total sample, the majority (86%) had Type 2 DM,
49% were diagnosed incidentally and most of them
(79%) had the disease for ≥ 10 years. Of the total popula-
tion 35% (95%CI: 30.8–39) had hypertension, 76% were
obese or overweight and 61% (95% CI: 56.7–65.7) had
microalbuminuria (MA) (Table 2). The majority of
patients (84%) partially managed the disease by oral
hypoglycemic agents, 24% by insulin while two thirds
were not following any exercise regime as part of their rou-
tine management. The analysis of glycemic control using
HbA1C showed that 38% (95%CI: 32.8–42.4) had good
control. High total cholesterol was present in 34.4%
(95%CI: 30.0–38.8), high triglycerides in 25.2% (95%CI:
21.1–29.3), high LDL in 53.4% (95%CI: 44.9–61.9)
while low HDL was present in 25.7% (95%CI: 18.5–32.9)
of the study population (Table 2).BMC Family Practice 2007, 8:59 http://www.biomedcentral.com/1471-2296/8/59
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Prevalence of Foot Complications
Of the total sample, 39% (95% CI: 35.1–43.7%) had PN
and 12% (95% CI: 8.8–14.4%) had PVD (Table 2).
Trophic skin and nail abnormality were present in 3%
(95% CI: 1.4–4.4%) of the sample population and symp-
toms including cramp-like-pain in legs or feet, tingling,
numbness, and burning sensations with a "stocking and
glove distribution" were frequently reported in 35% (95%
CI: 30.4–38.6%) of them. There were no cases of foot
deformity or amputation and only one case had previous
history of lower extremity ulceration.
The risk factors for neuropathy, predicted using univariate
analysis were: male gender (p = 0.006), age (p = 0.01), dis-
ease duration (p = 0.0001), poor level of education (p =
0.04), poor glycemic control (p = 0.006) and type 2 DM
(p < 0.006). The complication was also highly signifi-
cantly associated with other microangiopathic complica-
tions such as diabetic retinopathy (p = 0.001) and
presence of microalbuminuria (p = 0.01) (Table 3).
Predicted risk factors for PVD, using univariate analysis
were: male gender (p < 0.001), age (p < 0.001), incidental
diagnosis of diabetes (p = 0.006), duration of diabetes (p
< 0.001) and presence of hypertension (p = 0.01). The
complication was also highly significantly associated with
other chronic complications of diabetes such as retinopa-
thy (p = 0.009), cerebrovascular disease (p = 0.001) and
presence of coronary artery disease (p = 0.01) (Table 4).
The multivariate stepwise logistic regression analysis with
backward selection of PN on variables including sex, level
of education, age group, nationality group, type of DM,
duration of disease, presence of retinopathy, MA, and
HbA1c, showed that PN was only significantly associated
Table 2: Clinical Characteristics of DM Patients in Al-Ain 
District, UAE, 2003–2004 (n = 513)
n Percent (95% CI)
Type of DM
Type 1 68 13.6 (10.6–16.6)
Type 2 431 86.4 (83.4–89.4)
Mode of Diagnosis
Incidental 245 48.5 (44.1–52.9)
Screening 39 7.7 (5.4–10.0)
Symptomatic 221 43.8 (39.5–48.1)
Family History of DM
Present 270 54.3 (49.9–58.7)
Absent 227 45.7(41.3–50.1)
Duration of the Disease
< 1 year 33 6.6 (4.4–8.8)
1–5 years 199 40.0 (35.7–44.3)
6–10 years 161 32.3 (28.2–36.4)
11–20 years 98 19.7 (16.2–23.4)
>21 years 7 1.4 (0.4–2.4)
Hypertension
Present 178 34.9 (30.0–38.8)
Absent 332 65.1(61.0–69.2)
Total Cholesterol
High (>5.60 mmol/L) 152 34.4 (30.0–38.8)
Normal (≤ 5.60 mmol/L) 290 65.5(61.1–69.9)
Triglycerides
High (>2.10 mmol/L) 105 23.9 (19.9–27.9)
Normal (≤ 2.10 mmol/L) 334 76.1(72.1–80.1)
HDL
High (≥ 0.91 mmol/L) 104 74.3 (67.1–81.5)
Low (<0.91 mmol/L) 36 25.7 (18.5–32.9)
LDL
High (>3.4 mmol/L) 70 53.4(44.9–61.9)
Normal (≤ 3.4 mmol/L) 61 46.6(38.1–55.1)
Microalbuminuria
Present (>20 µg/min) 276 61.2 (56.7–65.7)
Absent (<20 µg/min) 175 38.8 (34.3–43.3)
HBA1c
Good control (<7%) 150 37.6(32.8–42.4)
Poor control (>7%) 246 62.4(57.6–67.2)
Peripheral Neuropathy
Present 199 39(35.1–43.7)
Absent 306 61(56.3–64.9)
Peripheral Vascular Disease
Present 59 12(8.8–14.4)
Absent 451 88(85.6–91.2)
Table 1: Socio-Demographic Characteristics of DM Patients in 
Al-Ain District, UAE, 2003–2004 (n = 513)
Variable name Prevalence of DM
n Percent (95% CI)
Sex
Male 264 51.5 (47.2–55.8)
Female 249 48.5 (44.2–52.8)
Level of Education
Illiterate 318 62.8 (58.6–67.0)
Completed primary school 99 19.6 (16.1–23.1)
Completed secondary school 60 11.9 (9.1–14.7)
Completed university 29 5.7 (3.7–7.7)
Age group (Years)
40 or less 81 15.8 (12.6–19.0)
41 – 49 137 26.8 (23–30.6)
50 – 59 154 30.1 (26.1–34.1)
60 or above 140 27.3 (23.4–31.2)
Nationality group
UAE 382 74.6 (70.8–78.4)
Arabs from Gulf countries 54 10.5 (7.8–13.2)
Arabs from other countries 54 10.5 (7.8–13.2)
Asians 22 4.3 (2.5–6.1)
Smoking
Current smoker 64 12.8 (11.0–14.6)
Ex smoker 41 8.2 (6.7–9.7)
BMI Group
Under weight (<18.5) 6 1.2 (0.2–2.2)
Healthy weight (18.5–24.99) 113 22.5 (18.8–26.2)
Overweight (25–29.99) 195 38.8 (34.5–43.1)
Obese (>30) 188 37.7(33.3–41.7)BMC Family Practice 2007, 8:59 http://www.biomedcentral.com/1471-2296/8/59
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with increased duration of disease (p = 0.001), UAE
nationality (p = 0.02) and presence of MA (p = 0.01)
(Table 5). It is worthy noting that MA remained signifi-
cantly associated with PN (p = 0.01) after adjusting for
age, type of DM, HbA1c, level of education and nationality
(logistic regression adjusted OR: 0.521; 95% CI: 0.313–
0.866). However, the MA effect disappeared when
adjusted for duration of disease, age group, type of DM,
HbA1c, level of education and nationality. The effect of
increased duration of disease remained highly signifi-
cantly associated with neuropathy (p = 0.002) even after
adjusting for nationality, presence of MA, HbA1c, educa-
tion, sex, age and nationality (logistic regression adjusted
OR: 0.670; 95% CI: 0.520–0.864).
The multivariate stepwise logistic regression analysis with
backward selection of PVD on variables including sex, age
group, level of education, duration of disease, mode of
diagnosis, type of DM, presence of hypertension, HbA1c
and presence of MA revealed that only male, (adjusted
OR: 0.275; 95% CI: 0.124 – 0.611), increased duration of
disease (adjusted OR: 0.441; 95% CI: 0.288 – 0.676), low
level of education (adjusted OR: 2.869; 95% CI: 1.448 –
5.685), type 2 DM (adjusted OR: 0.110; 95% CI: 0.014 –
0.882), presence of hypertension (adjusted OR: 2.361)
were significantly associated with PVD (Table 6).
Discussion
The present study is the first study in the UAE investigat-
ing the risk factors of diabetic foot complications. As
Table 3: Peripheral Neuropathy (PN) in relation to Baselines Characteristics of the Study Population in Al-Ain District, UAE, 2003–
2004 (n = 513)
Variable name Presence of Neuropathy Absence of Neuropathy
n Percent (95% CI) n Percent (95% CI) p-value
Sex 0.006
Male 118 59.3(52.47–66.13) 143 46.7(41.1152.29)
Female 81 40.7(33.87–47.53) 163 53.3(47.7158.89)
Level of Education 0.040
Illiterate 116 59.5(52.6–66.4) 197 65(59.6–70.4)
Completed primary school 33 16.9(11.6–22.2) 64 21.1(16.5–25.7)
Completed secondary school 32 16.4(11.2–21.6) 27 8.9(5.7–12.1)
Completed university 14 7.2(3.6–10.8) 15 5(2.5–7.5)
Age group (Years) 0.015
40 or less 23 11.6(7.2–16.0) 57 18.7(14.3–23.1)
41 – 49 46 23.1(17.2–29.0) 91 29.8(24.7–34.9)
50 – 59 72 36.2(29.5–42.9) 80 26.2(21.3–31.1)
60 or above 58 29.1(22.8–35.4) 77 25.2(20.3–30.1)
Nationality group 0.014
UAE 140 70.7(64.36–77.04) 237 77.5(72.82–82.18)
Arabs from Gulf countries 16 8.1(4.30–11.90) 35 11.4(7.84–14.96)
Arabs from other countries 31 15.7(10.63–20.77) 23 7.5 (4.55–10.45)
Asians 11 5.6(2.40–8.80) 11 3.6 (1.51–5.69)
Type of DM 0.006
Type 1 37 19.2 31 10.4(6.93–13.87)
Type 2 156 80.8 267 89.6(86.13–93.07)
Duration of the Disease 0.000
< 1 year 15 7.6 17 5.8(3.12–8.48)
1–5 years 54 27.3 143 49(43.27–54.73)
6–10 years 68 34.3 90 30.8(25.50–36.10)
11–20 years 57 28.8 39 13.4(9.49–17.31)
>21 years 4 2 3 1(0.00–2.14)
Retinopathy 0.000
Present 35 30.4 31 13.8(9.29–18.31)
Absent 80 69.6 194 86.2(81.69–90.71)
Microalbuminuria 0.012
Present (>20 µg/min) 118 69.4 157 42.5(36.64–48.36)
Absent (< 20 µg/min) 52 30.6 116 57.5(51.64–63.36)
HAB1C 0.006
Good control (<7%) 50 33.1 144 40.7(34.52–46.88)
Poor control (>7%) 101 66.9 99 59.3(53.12–65.48)BMC Family Practice 2007, 8:59 http://www.biomedcentral.com/1471-2296/8/59
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proved elsewhere, our results, clearly demonstrate that
DM eventually lead to chronic complications, including
PVD and PN. It is known that PVD and PN are potential
risk factors for foot complications. Indeed, with the high
prevalence rates of DM in the UAE population and the
high rates of PVD and PN among patients which has been
revealed in this study, it is vital to observe for diabetes foot
complications.
The results of this study showed that the overall preva-
lence of PN was 39%, which was higher than the equiva-
lent rates reported in other populations [7,18-21].
Comparatively, the rate revealed for PVD (12%) in the
UAE population was far lower than that reported in other
populations [22-24]. However, the fact that 35% (95% CI:
30.4–38.6%) of the sample population reported to have
symptoms of neuropathy and/or vasculopathy and 3%
had trophic skin and nails, is a clear indication that they
are at increasing risk of developing foot complications in
the future. The high prevalence of PN compared with the
relatively low prevalence of PVD in the study population
can be due to methodological biases for diagnosing neu-
ropathy. Although the sensitivity and specifity of the DNS
score were high when defined using other standard clini-
Table 5: Multivariate Analysis of Risk Factors for PN among DM Patients in Al-Ain District, UAE, 2003–2004 using stepwise Logistic 
Regression
Variable Regression coefficient P value Adjusted OR 95% CI
UAE Nationality -0.299 0.029 0.741 (0.567–0.970)
Increased DM duration -0.431 0.001 0.650 (0.502–0.842)
Presence of MA -0.651 0.013 0.522 (0.312–0.871)
Table 4: Peripheral Vascular Disease (PVD) in Relation to Baseline Characteristics ofthe Study Population in Al-Ain District, UAE, 
2003–2004 (n = 513)
Variable name Presence of PVD Absence of PVD
n Percent (95% CI) n Percent (95% CI) p-value
Sex
Male 44 74.6(63.4985.71) 217 48.1(43.4952.71) 0.000
Female 15 25.4(14.2936.51) 234 51.9(47.2956.51)
Age group (Years)
40 or less 3 5.1(0.00–10.71) 78 17.3(13.81–20.79) 0.000
41 – 49 8 13.6(4.85–22.35) 129 28.7(24.52–32.88)
50 – 59 16 27.1(15.76–38.44) 136 30.2(25.96–34.44)
60 or above 32 54.2(41.49–66.91) 107 23.8(19.87–27.73)
Duration of the Disease
< 1 year 1 1.7(0.00–5.00) 31 7.1(4.69–9.51) 0.000
1–5 years 12 20.3(10.04–30.56) 186 42.7(38.06–47.34)
6–10 years 2 35.6(23.38–47.82) 140 32.1(27.72–36.48)
11–20 years 23 39(26.55–51.45) 74 17(13.47–20.53)
>21 years 2 3.4(0.00–8.02) 5 1.1(0.12–2.08)
Mode of diagnosis
Incidental 38 67.9(55.67–80.13) 206 46.2(41.57–50.83) 0.006
Screening 1 1.8(0.00–5.28) 38 8.5(5.91–11.09)
Symptomatic 17 30.4(18.35–42.45) 203 45.3(40.68–49.92)
Retinopathy
Present 16 33.3(19.97–46.63) 51 17.2(12.91–21.49) 0.009
Absent 32 66.7(53.37–80.03) 246 82.8(78.51–87.09)
Coronary Artery Disease
Present 17 28.8(17.25–40.35) 56 12.6(9.52–15.68) 0.001
Absent 42 71.2(59.65–82.75) 389 87.4(84.32–90.48)
Cerebrovascular disease
Present 5 8.6(1.38–15.82) 12 2.7(1.20–4.20) 0.018
Absent 53 91.4(84.18–98.62) 435 97.3(95.80–98.80)
Hypertension
Present 29 49.2(36.44–61.96) 148 33(28.65–37.35) 0.015
Absent 30 50.8(38.04–63.56) 300 67(62.65–71.35)BMC Family Practice 2007, 8:59 http://www.biomedcentral.com/1471-2296/8/59
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cal methods [16]. However, symptom scores may be less
reliable due to their subjectivity.
The results also showed that history of previous leg ulcer-
ation, deformity, gangrene and amputation were infre-
quently reported in the population; an issue which might
reflect a systematic sampling bias due to the fact that the
majority of the sample populations (82%) were recruited
from primary health care centers (PHCC). It is known and
naturally expected that diabetic patients with severe com-
plications tend to report and follow up in hospitals and
not in PHCC.
The multivariate logistic regression analysis further
showed that the main risk factors for PN and PVD and
thus potentially for foot complications were male gender,
poor level of education, UAE nationality, increased dis-
ease duration (10–12 years), type 2 DM, presence of
hypertension and MA. The results are consistent with find-
ings elsewhere [18,25-29]. It is known that the risk of
ulcers and lower limb amputations is higher in males, in
patients with diabetes duration of 10 years or more, those
who have poor glycemic control or have other cardiovas-
cular, retinal or renal complications [30]. Indeed, the fact
that the majority of the surveyed population (63%) were
illiterate and that 62% of them were of poor glycemic con-
trol; and, the fact that poor foot care is common among
patients and practitioners as well, as reported elsewhere
[31-33], reveal the extent, gravity and complexity of the
problem in the UAE.
It is interesting to note that MA was the only modifiable
risk factor for PN, revealed in the study and the result is
consistent with similar studies elsewhere [20,22,34].
However, some studies suggest that increased urinary
albumin might be a marker for endothelial damage, the
function of which may be the common cause of both
microalbuminuria and diabetic neuropathy [35,36].
Similarly, the analysis revealed that hypertension is the
only modifiable risk factor for PVD in the study popula-
tion, and the result is consistent with findings elsewhere
[21,37-39].
Conclusion
The study emphasizes the importance of early detection
for PVD and PN among diabetic patients in the UAE,
using simple affordable tools and methods. The introduc-
tion of such strategy is pivotal in any program aiming to
reduce the burden of diabetic foot complications.
Limitations
The study had few limitations. The study was unable to
correlate the clinical findings with electrophysiological
and morphologic findings for neuropathy such as nerve
conduction studies. Likewise, PVD was not investigated
using non-invasive vascular assessments such as the ankle
brachial pressure index that may have permitted refining
the data. However, despite the limitations mentioned and
the limited resources; this first population based survey
was able to disclose important information about the dia-
betic foot problem in the UAE, using simple methods that
could be used widely by clinicians to identify foot prob-
lems even in remote settings.
Recommendations
With the presence of high rates of MA in the population
(61%) it is imperative to emphasize the importance of
regular screening for MA in all diabetic patients, as early
screening and treatment are shown to reduce cardiovascu-
lar risk, such as neuropathy and nephropathy. Early
screening of diabetic patients for hypertension is equally
important in order to prevent cardiovascular complica-
tions such as PVD. Regular screening for foot complica-
tions is recommended to all patients in view of the high
rates reported for PN and PVD in the population. Treating
physicians should be encouraged to exert more attention
and care to foot examination, especially among the eld-
erly and illiterate patients; as ample evidence from the
study proves that potential risk factors for foot complica-
tions are highly significantly associated with illiteracy.
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